معرفی
Kevin M. Haigis is a Professor of Medicine at Harvard Medical School and serves as the Chief Scientific Officer at the Dana-Farber Cancer Institute. His work bridges experimental and computational approaches to understand the molecular basis of gastrointestinal cancers, particularly focusing on RAS signaling pathways.
Research Interests:
- RAS signaling in cancer
- Genetic and signaling networks in tumorigenesis
- Therapeutic responses in colorectal cancer
- Inflammation and cancer interplay
His research integrates genetically engineered mouse models and human cancer systems with computational and informatic tools to dissect oncogenic mechanisms. The recent publications highlight a strong emphasis on post-translational regulation of mutant KRAS, tissue-specific oncogenicity, and cross-species proteogenomic modeling, pointing to a trajectory toward precision oncology and targeted therapy development.
Scientific Awards:
- Robert Black Fellow, Damon Runyon Cancer Research Foundation
- Howard Temin Award K01, National Cancer Institute
Dr. Haigis leads a multidisciplinary research program at Dana-Farber, mentoring trainees and collaborating with leading cancer scientists. His work is supported by major grants from the NCI and other institutions, enabling translational research from bench to bedside. He has played key roles in identifying novel regulatory mechanisms of RAS and developing strategies to target previously undruggable oncogenes.
Laboratories and Collaborative Teams: Dr. Haigis leads a research laboratory at Dana-Farber that fosters collaboration with experts in proteomics, chemical biology, and cancer genomics. His team works closely with investigators such as William C. Hahn, Nathanael Gray, Joseph Mancias, and others in the Broad Institute and Dana-Farber community.
